FilingReader Intelligence

Jiangxi Synergy secures Korean drug registration certificate

February 17, 2025 at 05:50 PM UTCBy FilingReader AI

Jiangxi Synergy Pharmaceutical (SZSE:300636) announced that it has received a drug registration certificate from the South Korean Ministry of Food and Drug Safety (MFDS) for its Mirabegron product. The certification, numbered 2025-A1-0278 and issued on February 12, 2025, covers Mirabegron raw materials produced at the company's facility in the Fengxin High-tech Industrial Park, Jiangxi Province. Mirabegron, a selective β3-adrenergic receptor agonist, is used to treat symptoms of overactive bladder. The company stated that this approval signifies market entry for its Mirabegron raw material in South Korea and is expected to contribute positively to the expansion of its international business. However, Synergy also cautioned investors that sales are subject to market conditions and exchange rate fluctuations, advising them to exercise prudence and be aware of investment risks.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Jiangxi Synergy Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →